Last reviewed · How we verify

Seretide® Accuhaler® 250/50 µg/actuation

Chiesi Farmaceutici S.p.A. · Phase 3 active Small molecule

Seretide® Accuhaler® 250/50 µg/actuation is a Long-acting beta-2 agonist / Inhaled corticosteroid combination (LABA/ICS) Small molecule drug developed by Chiesi Farmaceutici S.p.A.. It is currently in Phase 3 development for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation.

Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

At a glance

Generic nameSeretide® Accuhaler® 250/50 µg/actuation
SponsorChiesi Farmaceutici S.p.A.
Drug classLong-acting beta-2 agonist / Inhaled corticosteroid combination (LABA/ICS)
TargetBeta-2 adrenergic receptor; Glucocorticoid receptor
ModalitySmall molecule
Therapeutic areaRespiratory / Pulmonology
PhasePhase 3

Mechanism of action

Salmeterol activates beta-2 adrenergic receptors on airway smooth muscle, causing bronchodilation and lasting 12 hours. Fluticasone propionate is a corticosteroid that binds glucocorticoid receptors to suppress inflammatory cytokine production and reduce airway edema and mucus secretion. Together, they provide both acute symptom relief and long-term anti-inflammatory control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Seretide® Accuhaler® 250/50 µg/actuation

What is Seretide® Accuhaler® 250/50 µg/actuation?

Seretide® Accuhaler® 250/50 µg/actuation is a Long-acting beta-2 agonist / Inhaled corticosteroid combination (LABA/ICS) drug developed by Chiesi Farmaceutici S.p.A., indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

How does Seretide® Accuhaler® 250/50 µg/actuation work?

Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation.

What is Seretide® Accuhaler® 250/50 µg/actuation used for?

Seretide® Accuhaler® 250/50 µg/actuation is indicated for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.

Who makes Seretide® Accuhaler® 250/50 µg/actuation?

Seretide® Accuhaler® 250/50 µg/actuation is developed by Chiesi Farmaceutici S.p.A. (see full Chiesi Farmaceutici S.p.A. pipeline at /company/chiesi-farmaceutici-s-p-a).

What drug class is Seretide® Accuhaler® 250/50 µg/actuation in?

Seretide® Accuhaler® 250/50 µg/actuation belongs to the Long-acting beta-2 agonist / Inhaled corticosteroid combination (LABA/ICS) class. See all Long-acting beta-2 agonist / Inhaled corticosteroid combination (LABA/ICS) drugs at /class/long-acting-beta-2-agonist-inhaled-corticosteroid-combination-laba-ics.

What development phase is Seretide® Accuhaler® 250/50 µg/actuation in?

Seretide® Accuhaler® 250/50 µg/actuation is in Phase 3.

What are the side effects of Seretide® Accuhaler® 250/50 µg/actuation?

Common side effects of Seretide® Accuhaler® 250/50 µg/actuation include Tremor, Headache, Palpitations, Muscle cramps, Oral candidiasis, Hoarseness.

What does Seretide® Accuhaler® 250/50 µg/actuation target?

Seretide® Accuhaler® 250/50 µg/actuation targets Beta-2 adrenergic receptor; Glucocorticoid receptor and is a Long-acting beta-2 agonist / Inhaled corticosteroid combination (LABA/ICS).

Related